PURPOSE: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is recommended for patients with acute coronary syndrome and after percutaneous coronary intervention with stenting in stable coronary artery disease to help prevent further thromboembolic events. However, there is limited guidance on appropriate strategies for switching between oral P2Y12 inhibitors. The aim of this study was to evaluate safety of switching modalities at our institution and compare them to the recently published expert consensus recommendations. METHODS: This was a retrospective, descriptive analysis of patients admitted to Brigham and Women's Hospital from January 2015 to December 2018. Patients were included if they were at least 18 years of age and had documented administrations of two or more oral P2Y12 inhibitors during the same admission. The major safety endpoint was incidence of major adverse cardiac events (MACE) (cardiovascular death, myocardial infarction, stroke, and non-coronary artery bypass grafting (CABG)-related bleeding) at seven days or until hospital discharge. Minor endpoints included the incidence of in-stent thrombosis, number of patients who received appropriate loading doses (LD) before and after the recently published recommendations, and documented reason for switching between agents. RESULTS: There were 253 patients included in the final analysis. Of these, 83 patients were on clopidogrel as the first agent prior to switching, 9 patients were on prasugrel, and 161 were on ticagrelor. There was no incidence of the primary safety endpoint observed in any group. However, the number of patients who received a LD when switching between oral P2Y12 inhibitors increased from 80.0% to 87.0% after publication of the expert consensus paper. The most common reasons for switching from one agent to another were cost/insurance coverage (19.0%), need for triple therapy (16.0%), and bleeding risk (11.0%). CONCLUSION: Different switching modalities were not associated with an increase in MACE at our institution; however, larger randomized controlled trials are warranted. AJCD
PURPOSE: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is recommended for patients with acute coronary syndrome and after percutaneous coronary intervention with stenting in stable coronary artery disease to help prevent further thromboembolic events. However, there is limited guidance on appropriate strategies for switching between oral P2Y12 inhibitors. The aim of this study was to evaluate safety of switching modalities at our institution and compare them to the recently published expert consensus recommendations. METHODS: This was a retrospective, descriptive analysis of patients admitted to Brigham and Women's Hospital from January 2015 to December 2018. Patients were included if they were at least 18 years of age and had documented administrations of two or more oral P2Y12 inhibitors during the same admission. The major safety endpoint was incidence of major adverse cardiac events (MACE) (cardiovascular death, myocardial infarction, stroke, and non-coronary artery bypass grafting (CABG)-related bleeding) at seven days or until hospital discharge. Minor endpoints included the incidence of in-stent thrombosis, number of patients who received appropriate loading doses (LD) before and after the recently published recommendations, and documented reason for switching between agents. RESULTS: There were 253 patients included in the final analysis. Of these, 83 patients were on clopidogrel as the first agent prior to switching, 9 patients were on prasugrel, and 161 were on ticagrelor. There was no incidence of the primary safety endpoint observed in any group. However, the number of patients who received a LD when switching between oral P2Y12 inhibitors increased from 80.0% to 87.0% after publication of the expert consensus paper. The most common reasons for switching from one agent to another were cost/insurance coverage (19.0%), need for triple therapy (16.0%), and bleeding risk (11.0%). CONCLUSION: Different switching modalities were not associated with an increase in MACE at our institution; however, larger randomized controlled trials are warranted. AJCD
Authors: Dominick J Angiolillo; Nicholas Curzen; Paul Gurbel; Paul Vaitkus; Fred Lipkin; Wei Li; Joseph A Jakubowski; Marjorie Zettler; Mark B Effron; Dietmar Trenk Journal: J Am Coll Cardiol Date: 2013-12-12 Impact factor: 24.094
Authors: Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao; Jeffrey L Anderson; Alice K Jacobs; Jonathan L Halperin; Nancy M Albert; Ralph G Brindis; Mark A Creager; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; Frederick G Kushner; E Magnus Ohman; William G Stevenson; Clyde W Yancy Journal: Circulation Date: 2012-12-17 Impact factor: 29.690
Authors: Dominick J Angiolillo; Fabiana Rollini; Robert F Storey; Deepak L Bhatt; Stefan James; David J Schneider; Dirk Sibbing; Derek Y F So; Dietmar Trenk; Dimitrios Alexopoulos; Paul A Gurbel; Willibald Hochholzer; Leonardo De Luca; Laurent Bonello; Daniel Aradi; Thomas Cuisset; Udaya S Tantry; Tracy Y Wang; Marco Valgimigli; Ron Waksman; Roxana Mehran; Gilles Montalescot; Francesco Franchi; Matthew J Price Journal: Circulation Date: 2017-10-30 Impact factor: 29.690
Authors: Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; José Luis Zamorano Journal: Rev Esp Cardiol (Engl Ed) Date: 2018-01
Authors: Francesco Franchi; Gabriel Todd Faz; Fabiana Rollini; Yongwhi Park; Jung Rae Cho; Estela Thano; Jenny Hu; Megha Kureti; Niti Aggarwal; Ashwin Durairaj; Latonya Been; Martin M Zenni; Luis A Guzman; Siva Suryadevara; Patrick Antoun; Theodore A Bass; Dominick J Angiolillo Journal: JACC Cardiovasc Interv Date: 2016-03-21 Impact factor: 11.195
Authors: Dominick J Angiolillo; Jorge F Saucedo; Roger Deraad; Andrew L Frelinger; Paul A Gurbel; Timothy M Costigan; Joseph A Jakubowski; Clement K Ojeh; Mark B Effron Journal: J Am Coll Cardiol Date: 2010-09-21 Impact factor: 24.094
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Thomas Cuisset; Pierre Deharo; Jacques Quilici; Thomas W Johnson; Stéphanie Deffarges; Clémence Bassez; Guillaume Bonnet; Laurent Fourcade; Jean Philippe Mouret; Marc Lambert; Valentine Verdier; Pierre Emmanuel Morange; Marie Christine Alessi; Jean Louis Bonnet Journal: Eur Heart J Date: 2017-11-01 Impact factor: 29.983